• Vaxcyte closed a USD 575 million offering of 1.50% convertible senior notes due 2032.
• Underwriters fully exercised an option to buy an additional USD 75 million of notes to cover over-allotments.
• Gross proceeds from the concurrent equity, warrant, and note offerings totaled about USD 1.15 billion.
• Net proceeds earmarked for VAX-31 clinical development, manufacturing scale-up, and launch preparation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610091605PRIMZONEFULLFEED9843160) on October 09, 2026, and is solely responsible for the information contained therein.